Mostrar el registro sencillo del ítem
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
dc.creator | Michel M.C., Gravas S. | en |
dc.date.accessioned | 2023-01-31T08:59:53Z | |
dc.date.available | 2023-01-31T08:59:53Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1517/14740338.2016.1160055 | |
dc.identifier.issn | 14740338 | |
dc.identifier.uri | http://hdl.handle.net/11615/76619 | |
dc.description.abstract | Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss them mechanistically in the context of expression and other preclinical data.Areas covered: Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. Hypertension is the most frequently observed adverse event, but has a similar incidence with mirabegron and placebo. Nevertheless, severe uncontrolled hypertension has become a contraindication for use of mirabegron based on observation of severe hypertension in association with mirabegron exposure. The overall incidence of adverse events is also similar between mirabegron and the muscarinic receptor antagonist tolterodine, but the incidence of dry mouth is much lower with mirabegron.Expert opinion: The high β3-adrenoceptor mRNA expression in the human ovaries is not associated with reproductive side effects. Generally, β3-adrenoceptors exhibit a rather restricted expression in human tissues, which may explain the overall good tolerability of agonists acting on this receptor. We propose that expression profiles and functional preclinical studies can be important tools in the prediction of adverse event profiles in first-in-class drugs. © 2016 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language.iso | en | en |
dc.source | Expert Opinion on Drug Safety | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961390353&doi=10.1517%2f14740338.2016.1160055&partnerID=40&md5=efe3f08bc981a8d726d456094282eba0 | |
dc.subject | beta 3 adrenergic receptor stimulating agent | en |
dc.subject | beta adrenergic receptor | en |
dc.subject | mirabegron | en |
dc.subject | muscarinic receptor blocking agent | en |
dc.subject | placebo | en |
dc.subject | solabegron | en |
dc.subject | solifenacin | en |
dc.subject | tolterodine | en |
dc.subject | transcriptome | en |
dc.subject | acetanilide derivative | en |
dc.subject | aniline derivative | en |
dc.subject | benzoic acid derivative | en |
dc.subject | beta 3 adrenergic receptor | en |
dc.subject | beta 3 adrenergic receptor stimulating agent | en |
dc.subject | biphenyl derivative | en |
dc.subject | mirabegron | en |
dc.subject | solabegron | en |
dc.subject | thiazole derivative | en |
dc.subject | aged | en |
dc.subject | constipation | en |
dc.subject | drug safety | en |
dc.subject | drug tolerability | en |
dc.subject | drug withdrawal | en |
dc.subject | experimental study | en |
dc.subject | headache | en |
dc.subject | human | en |
dc.subject | hypertension | en |
dc.subject | incidence | en |
dc.subject | meta analysis (topic) | en |
dc.subject | multicenter study (topic) | en |
dc.subject | overactive bladder | en |
dc.subject | phase 2 clinical trial (topic) | en |
dc.subject | phase 3 clinical trial (topic) | en |
dc.subject | protein expression | en |
dc.subject | protein function | en |
dc.subject | randomized controlled trial (topic) | en |
dc.subject | Review | en |
dc.subject | rhinopharyngitis | en |
dc.subject | systematic review (topic) | en |
dc.subject | urinary tract infection | en |
dc.subject | urine retention | en |
dc.subject | xerostomia | en |
dc.subject | animal | en |
dc.subject | drug effects | en |
dc.subject | gene expression profiling | en |
dc.subject | genetics | en |
dc.subject | pathophysiology | en |
dc.subject | Urinary Bladder, Overactive | en |
dc.subject | Acetanilides | en |
dc.subject | Adrenergic beta-3 Receptor Agonists | en |
dc.subject | Aniline Compounds | en |
dc.subject | Animals | en |
dc.subject | Benzoates | en |
dc.subject | Biphenyl Compounds | en |
dc.subject | Gene Expression Profiling | en |
dc.subject | Humans | en |
dc.subject | Receptors, Adrenergic, beta-3 | en |
dc.subject | Thiazoles | en |
dc.subject | Urinary Bladder, Overactive | en |
dc.subject | Taylor and Francis Ltd | en |
dc.title | Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies | en |
dc.type | other | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |